EUVIMEDOpdag EUVIMED
Open access

Potential drug–drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the National Covid Cohort Collaborative (N3C)

Xuya Xiao iD, Hemalkumar B Mehta iD, Jill Curran, Brian T Garibaldi, G Caleb Alexander, National Covid Cohort Collaborative (N3C) Consortium

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-12 · 43 (12) · 1251-1261

DOI: 10.1002/phar.2860 ↗

At a glance

Journal article in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2023-08-21. Written by Xuya Xiao and 5 co-authors. Institution: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Major MEDLINE topics: COVID-19. Cited 8 times so far (Crossref); 29 references. The full text is freely available in PubMed Central. Funded by: NCATS NIH HHS, NIGMS NIH HHS, NIA NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Study Objective To estimate the prevalence of potential moderate to severe drug–drug interactions (DDIs) involving nirmatrelvir/ritonavir, identify interacting medications, and evaluate risk factors associated with potential DDIs.

Design

Cross‐sectional study. Data Source Electronic health records from the National COVID Cohort Collaborative Enclave, one of the largest COVID‐19 data resources in the United States. Patients Outpatients aged ≥18 years and started nirmatrelvir/ritonavir between December 23, 2021 and March 31, 2022.

Intervention

Nirmatrelvir/ritonavir.

Measurements

The outcome is potential moderate to severe DDIs, defined as starting interacting medications reported by National Institutes of Health 30 days before or 10 days after starting nirmatrelvir/ritonavir. Main Results Of 3214 outpatients who started nirmatrelvir/ritonavir, the mean age was 56.8 ± 17.1 years, 39.5% were male, and 65.8% were non‐Hispanic white. Overall, 521 (16.2%) were potentially exposed to at least one moderate to severe DDI, most commonly to atorvastatin (19.2% of all DDIs), hydrocodone (14.0%), or oxycodone (14.0%). After adjustment for covariates, potential DDIs were more likely among individuals who were older (odds ratio [OR] 1.16 per 10‐year increase, 95% confidence interval [CI] 1.08–1.25), male (OR 1.36, CI 1.09–1.71), smokers (OR 1.38, CI 1.10–1.73), on more co‐medications (OR 1.35, CI 1.31–1.39), and with a history of solid organ transplant (OR 3.63, CI 2.05–6.45).

Conclusions

One in six of individuals receiving nirmatrelvir/ritonavir were at risk of a potential moderate or severe DDI, underscoring the importance of clinical and pharmacy systems to mitigate such risks.

Subjects

MeSH terms (MEDLINE)

COVID-19AdultHumansMaleAdolescentMiddle AgedAgedFemaleCOVID-19 Drug TreatmentCross-Sectional StudiesRitonavirAntiviral AgentsLactamsLeucineNitrilesProline

Author keywords

SARS-CoV-2antiviralsdrug interactionsdrug safetynirmatrelvir/ritonavirpatient safety

Substances

RitonavirAntiviral AgentsnirmatrelvirLactamsLeucineNitrilesProline

Authors and institutions

  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Division of General Internal Medicine, Johns Hopkins Medicine, Baltimore, Maryland, USA.

ORCID profiles: Xuya Xiao, Hemalkumar B Mehta

Funding

  • NCATS NIH HHS
  • NIGMS NIH HHS
  • NIA NIH HHS
  • NHLBI NIH HHS

Cite

APA

Xiao, X., Mehta, H. B., Curran, J., Garibaldi, B. T., Alexander, G. C., & National Covid Cohort Collaborative (N3C) Consortium (2023). Potential drug–drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the National Covid Cohort Collaborative (N3C). Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(12), 1251-1261. https://doi.org/10.1002/phar.2860

Vancouver

Xiao X, Mehta HB, Curran J, Garibaldi BT, Alexander GC, National Covid Cohort Collaborative (N3C) Consortium. Potential drug–drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the National Covid Cohort Collaborative (N3C). Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(12):1251-1261. doi:10.1002/phar.2860

BibTeX
@article{Xiao2023,
  author = {Xiao, Xuya and Mehta, Hemalkumar B and Curran, Jill and Garibaldi, Brian T and Alexander, G Caleb and National Covid Cohort Collaborative (N3C) Consortium, National Covid Cohort Collaborative (N3C) Consortium},
  title = {Potential drug–drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the National Covid Cohort Collaborative (N3C)},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  volume = {43},
  number = {12},
  pages = {1251--1261},
  doi = {10.1002/phar.2860}
}
Start for free →